Gala­pa­gos spot­lights an 'ex­cit­ing' round of PoC da­ta for IPF drug, shares surge

Gala­pa­gos $GLPG says it got the proof-of-con­cept da­ta re­searchers were look­ing for from their mid-stage tri­al of GLPG1690 for id­io­path­ic pul­monary fi­bro­sis and will now push for­ward as planned in­to a piv­otal pro­gram.

Fast on the heels of a ri­otous re­cep­tion for Fi­bro­Gen’s PoC round for a ri­val IPF drug, the Bel­gian biotech says their drug clear­ly sta­bi­lized a small group of pa­tients with the dis­ease while pa­tients in the place­bo arm con­tin­ued to de­cline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.